pyrazines has been researched along with belinostat in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ara, G; Chen, Z; Duan, J; Friedman, J; Nottingham, L; Van Waes, C | 1 |
| Anderson, G; Belani, C; Feng, R; Lentzsch, S; Mapara, MY; Oton, A | 1 |
| Chen, S; Dai, Y; Dent, P; Funk, VL; Grant, S; Kramer, LB | 1 |
| Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, J | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Wang, L | 1 |
| Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ | 1 |
| Afqir, S; Belbaraka, R; Benjaafar, N; Elmajjaoui, S; Errihani, H; Ismaili, N; Tahri, A | 1 |
1 trial(s) available for pyrazines and belinostat
| Article | Year |
|---|---|
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Drug Synergism; Female; Histone Deacetylase 6; Histone Deacetylases; HL-60 Cells; Humans; Hydroxamic Acids; I-kappa B Kinase; Jurkat Cells; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrazines; Signal Transduction; Sulfonamides; Transcription Factor RelA; Tubulin; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
6 other study(ies) available for pyrazines and belinostat
| Article | Year |
|---|---|
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; NF-kappa B p50 Subunit; Proteasome Inhibitors; Protein Binding; Pyrazines; RNA, Small Interfering; Sulfonamides; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2007 |
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; Osteogenesis; Oxidative Stress; Proto-Oncogene Proteins; Pyrazines; Reactive Oxygen Species; Sulfonamides | 2007 |
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Depsipeptides; Drug Synergism; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Sulfonamides | 2008 |
Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxamic Acids; Lymphoma, Mantle-Cell; Mice; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides | 2011 |
[Urological cancers: ECCO/ESMO congress 2011].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Medical Oncology; Pyrazines; Societies, Medical; Sulfonamides; Sweden; Urologic Neoplasms | 2012 |